Founded by Dr. Li Chen 2011, Hua Medicine (Shanghai) Ltd. is a leading clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Hua has several innovative assets with global rights, and the most advanced one is dorzagliatin (HMS5552), a first-in-class oral drug for the treatment of Type 2 Diabetes (T2D). Dorzagliatin has advanced into NDA-enabling stage and is currently being evaluated in T2D patients in two Phase 3 trials in China, plus various early phase trials in both China and US. An NDA will be submitted for marketing approval in China following the successful completion of Phase 3 registration trials.
As an important "glucose sensor", glucokinase plays a central role in the regulation of glucose homeostasis in human. Impaired glucokinase function leads to glucose sensing defect, resulting in abnormal increase in blood glucose levels, disruption of glucose homeostasis and lipid metabolism, leading to diabetes, metabolic syndrome as well as a series of diabetic complications. As a novel allosteric GK activator, dorzagliatin has demonstrated the potential to repair the defective glucokinase function and restore glucose homeostasis. Dorzagliatin holds the potential to become transformative, especially in the management of T2D and diabetic complications which cannot be effectively controlled by currently available antidiabetic drugs.
At Hua Medicine, our mission is "to meet the needs of patients and to lead the pharmaceutical innovation in China". We are taking the "Patients first – Global innovation – Effective medicines" approach, and actively establishing partnerships with leading experts world-wide. We are constantly looking for innovative assets with potential to address unmet medical needs, especially for patients in China. At the same time, we have established an innovative operational model (VIC+Q and PPP+Q), aiming to achieve joint innovation by combining knowledge from China and the Western world while striving for global originality and creativity through integrating global pharmaceutical R&D resources.